Transcatheter Hepatic Artery Chemoembolization Combined With Immune Checkpoint Inhibitors for Liver Tumors
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
• Sign informed consent
• When screening for age, the age should be ≥ 18 years old
• Eligible for TACE treatment
• ECOG physical condition score is 0 or 1
• No prior systemic therapy for HCC, especially immunotherapy
• According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation
Locations
Other Locations
China
Tianjin Medical University Cancer Institute and Hospital
RECRUITING
Tianjin
Contact Information
Primary
Haipeng Yu
jieruke@163.com
022-23340123
Time Frame
Start Date: 2020-10-27
Estimated Completion Date: 2026-10-27
Participants
Target number of participants: 40
Treatments
Experimental: TACE combined ICI
TACE combined ICI
Related Therapeutic Areas
Sponsors
Leads: Tianjin Medical University Cancer Institute and Hospital